Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Expands By 11.8%

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 13,620,000 shares, an increase of 11.8% from the December 15th total of 12,180,000 shares. Based on an average trading volume of 3,500,000 shares, the short-interest ratio is currently 3.9 days.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ADMA shares. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Trading Down 3.7 %

NASDAQ:ADMA opened at $16.02 on Friday. The company has a market cap of $3.79 billion, a P/E ratio of 57.21 and a beta of 0.76. The stock’s fifty day moving average price is $19.04 and its two-hundred day moving average price is $17.29. ADMA Biologics has a 1 year low of $4.86 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the business posted $0.01 earnings per share. As a group, analysts expect that ADMA Biologics will post 0.52 EPS for the current year.

Insider Activity

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in ADMA. State Street Corp raised its position in shares of ADMA Biologics by 61.4% in the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after buying an additional 4,945,063 shares in the last quarter. Perpetual Ltd purchased a new stake in shares of ADMA Biologics in the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics during the third quarter valued at about $61,858,000. Bank of Montreal Can purchased a new stake in ADMA Biologics during the second quarter valued at about $17,886,000. Finally, D. E. Shaw & Co. Inc. raised its position in ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after purchasing an additional 1,442,799 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.